Raymond James Upgrades Biogen to Outperform, Announces $283 Price Target
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Danielle Brill has upgraded Biogen (NASDAQ:BIIB) from Market Perform to Outperform and set a price target of $283.

December 07, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biogen was upgraded by Raymond James from Market Perform to Outperform with a new price target of $283.
Analyst upgrades typically lead to positive short-term price movement as they suggest a better outlook for the company. The new price target of $283 implies a significant upside potential from the current trading price, which can attract investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100